Home Newsfeeds Canaccord Genuity Downgrades Cogeco Communications to Hold

Canaccord Genuity Downgrades Cogeco Communications to Hold

Canaccord Genuity analyst Aravinda Galappatthige downgrades Cogeco Communications (TSX:CCA) from Buy to Hold.

byBenzinga Newsdesk

October 20, 2022

1 minute read

Canaccord Genuity analyst Aravinda Galappatthige downgrades Cogeco Communications (TSX:CCA) from Buy to Hold.

Hertz Q1 Tops Earnings On Strong Demand And Pricing

By Lekha Gupta

April 27, 12:34 PM

Hertz Global Holdings Inc (NASDAQ:HTZ) reported Q1 2023 revenue growth of 13% Y/Y to $2.05 billion, beating the consensus of…

HTZ

Dow Tumbles Over 100 Points; US Producer Prices Decline In May

By Avi Kapoor

June 13, 9:45 AM

U.S. stocks traded mixed this morning, with the Dow Jones index falling by more than 100 points on…

BRTX

Salesforce Selects Ironclad As Contract Lifecycle Management Platform, Promising Streamlined Processes And Enhanced Insights

By Nabaparna Bhattacharya

April 3, 1:51 PM

Salesforce partners with Ironclad for streamlined contract management, heralding faster deals and enriched insights, while scaling operations.

CRM

New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

By Benzinga Newsdesk

October 3, 8:46 AM

Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor

DXR

Canaccord Genuity Downgrades Cogeco Communications to Hold

Related Posts

Hertz Q1 Tops Earnings On Strong Demand And Pricing

Dow Tumbles Over 100 Points; US Producer Prices Decline In May

Salesforce Selects Ironclad As Contract Lifecycle Management Platform, Promising Streamlined Processes And Enhanced Insights

New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care